Polyrizon Shares Surge After $17M Placement and Eurofins Manufacturing Pact
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Polyrizon Ltd (NASDAQ: PLRZ) is an Israel-based development-stage biotechnology company specializing in innovative intranasal medical device hydrogels. Its proprietary Capture and Contain™ (C&C) technology is designed to form a hydrogel barrier in the nasal cavity to block viruses and allergens. The company is also developing a Trap and Target™ (T&T) platform for intranasal delivery of active pharmaceutical ingredients (APIs).
Corporate Structure
Founded in 2005 and headquartered in Ra’anana, Polyrizon employs a team of 2–10 individuals. Its executive leadership includes Tomer Izraeli (Founder & CEO), Nir Ben Yosef (CFO), Daphna Avital (Chief People Officer), Dr. Tidhar Turgeman (CTO), Yuliya Yutkevich (QA & RA Director), and Dr. Eyal S. Ron (Chief Scientific Officer). A scientific advisory board features Prof. Avi Schroeder, Prof. Smadar Cohen, Prof. Fabio Sonvico, and Prof. Nancy Agmon-Levin, representing expertise in targeted drug delivery, biomaterials, formulations, and clinical immunology.
Intranasal Hydrogel by Hakan Nural
Developments and News
On March 31, 2025, Polyrizon entered into definitive agreements with institutional investors for a private placement totaling approximately $17.0 million. The offering consisted of 35,416,667 Ordinary Units priced at $0.48 each and included Series A warrants exercisable at $1.20 per share, contingent upon shareholder approval. The net proceeds are intended for general corporate purposes and working capital.
In November 2025, Polyrizon secured a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S. to supply clinical trial material for its PL-14 allergy blocker. This collaboration supports Good Manufacturing Practice (GMP) production ahead of a Phase I safety and efficacy study scheduled for 2025.
SEC filings in early December 2025 include:
- A Form 6-K (December 2, 2025) reporting the successful completion of a key manufacturing upscaling milestone for its nasal spray platform.
- A Form 6-K (December 3, 2025) announcing positive mucoadhesion results for an intranasal naloxone hydrogel in comparison to a marketed product.
- A Notice of Effectiveness (Form F-3, December 3, 2025) confirming the effectiveness of its registration statement, enabling further issuances of securities.
Financial and Strategic Analysis
As of December 4, 2025, Polyrizon’s share price closed at $15.10, reflecting an increase of 112.96% on the day, with a trading volume of 1,418,724 shares. The market capitalization was approximately $3.34 million. The company reported a net loss of $1.16 million for the trailing twelve months (TTM) and held $15.83 million in cash as of the most recent quarter. Its price-to-book ratio is 0.18.
| Metric | Value |
|---|---|
| Share Price (12/04/2025) | $15.10 |
| Day Change (%) | +112.96% |
| Volume | 1,418,724 |
| Market Cap | $3.34 M |
| Net Income (TTM) | -$1.16 M |
| Cash (MRQ) | $15.83 M |
| Price/Book (MRQ) | 0.18 |
The $17 million private placement enhances liquidity, augmenting existing cash reserves to support clinical and manufacturing activities. The agreement with Eurofins aligns production capacity with the upcoming PL-14 trial. The SEC’s Notice of Effectiveness provides options for future fundraising through its Form F-3 shelf registration.
Market Position and Industry Context
Polyrizon operates in the growing intranasal delivery segment, which is recognized for non-invasive drug administration and prophylactic barriers. The C&C hydrogel barrier aims to prevent pathogen entry, while the T&T platform focuses on therapeutic delivery—two strategies reflecting broader industry trends towards patient-friendly formulations. The competitive landscape includes other nasal spray developers and firms engaged in drug-device combinations. Regulatory pathways for medical device hydrogels may allow expedited market entry compared to traditional therapeutics, pending successful clinical outcomes and necessary approvals.
tl;dr
On December 4, 2025, Polyrizon’s stock closed at $15.10, marking an increase of 112.96%. The company completed a $17 million private placement on March 31, 2025, and established a manufacturing agreement with Eurofins for its PL-14 allergy blocker trial planned for 2025. Early December SEC filings confirmed milestones in manufacturing scale-up, positive data for an intranasal naloxone hydrogel, and the effectiveness of its shelf registration, which supports potential future capital raising and clinical advancement.